Economic evaluation of temsirolimus on the basis of the results of the ARCC (Advanced Renal-Cell Carcinoma) study

by Simona de Portu, Giacomo Carteni, Andrea Belisari
Published 2009-06-01

Economic evaluation of the use of saxagliptin in the treatment of type 2 diabetes in Italy

by Marco Cristiani, Anna Citarella, Andrea Belisari, Guido Didoni, Lorenzo Giovanni Mantovani, Sabato Montella
Published 2010-06-01

Economic impact of the use of Hyalubrix® in the treatment of hip osteoarthritis in Italy

by Alberto Migliore, Andrea Belisari, Lucia S. D'Angiolella, Emanuele Bizzi, Umberto Massafra, Prisco Piscitelli, Lorenzo Giovanni Mantovani
Published 2014-12-01

The use of dexmedetomidine in intensive care sedation

by Massimo Antonelli, Giorgio Conti, Andrea Belisari, Lucia S. D'Angiolella, Lorenzo Mantovani, Sabato Montella, Patrizio Piacentini, Marco Ranieri
Published 2013-05-01

[Budget impact analysis of idarucizumab for the management of patients treated with dabigatran in emergency / urgent situations in Italy]

by Andrea Belisari, Sergio Iannazzo, Giuseppe Di Pasquale, Claudio Fresco, Lorenzo Giovanni Mantovani, Maria Pia Ruggeri, Danilo Toni, Raffaele Landolfi
Published 2016-06-01

Cetuximab in first line treatment of metastatic colorectal cancer

by Carlo Barone, Andrea Belisari, Fortunato Ciardiello, Lorenzo Mantovani, Lucia D’Angiolella, Gianluca Furneri, Nicola Normanno, Patrizio Piacentini, Carmine Pinto
Published 2012-07-01

[Nintedanib for the treatment of idiopathic pulmonary fibrosis in Italy]

by Andrea Belisari, Daria Bettoni, Paolo Angelo Cortesi, Lucia Sara D'Angiolella, Lorenzo Giovanni Mantovani, Gerardo Miceli Sopo, Marino Nonis
Published 2017-04-01